Long-term Results of Therapy with Mycophenolate Mofetil in Ocular Mucous Membrane Pemphigoid

REFERENCES

• Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–561.
   PubMedGoogle Scholar
• Chan LS, Ahmed AR, Anhalt GR, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–379.
   PubMedGoogle Scholar
• Thorne JE, Anhalt GJ, Jabs DA, et al. Role of electron microscopy in the diagnosis of ocular mucous membrane pemphigoid. Ophthalmology. 2006;113(9):1651–1656.
   PubMedGoogle Scholar
• Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111(1):45–52.
   PubMedGoogle Scholar
• Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 1982;89(4):340–353.
   PubMedGoogle Scholar
• Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 1983;96(4):453–459.
   PubMedGoogle Scholar
• Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology. 2002;109(1):111–118.
   PubMedGoogle Scholar
• McCluskey P, Chang JH, Singh R, et al. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology. 2004;111(4):796–801.
   PubMedGoogle Scholar
• Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol. 2004;111(3):303–310.
   PubMedGoogle Scholar
• Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid. Ophthalmology. 2004;111(7):1380–1382.
   PubMedGoogle Scholar
• Thorne JE, Woreta FA, Jabs DA, et al. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology. 2008;115(12):2146–2152.
   PubMedGoogle Scholar
• Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. 2008;115(2):253–261.
   PubMed Web of Science ®Google Scholar
• Zurdel J, Aboalchamat B, Zierhut M, et al. Early clinical experiences with mycophenolate mofetil for immunosuppressive therapy of ocular cicatricial pemphigoid. Klin Monatsbl Augenheilkd. 2001;218(4):222–228.
   PubMedGoogle Scholar
• Megahed M, Schmiedeberg S, Becker J, et al. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2001;45(2):256–259.
   PubMedGoogle Scholar
• Ingen-Housz-Oro S, Prost-Squarcioni C, Pascal F, et al. Cicatricial pemphigoid: treatment with mycophenolate mofetil. Ann Dermatol Venerol. 2005;132(1):13–16.
   PubMedGoogle Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–432.
   PubMedGoogle Scholar
• Tauber J, Jabbur N, Foster CS. Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea. 1992;11(5):446–451.
   PubMedGoogle Scholar
• Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology. 1981;88(2):95–100.
   PubMedGoogle Scholar
• Elder MJ, Lightman S, Dart JK. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol. 1995;79(3):264–266.
   PubMedGoogle Scholar
• BenEzra D, Matamoros N, Cohen E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant Proc. 1988;20(2):644–649.
   PubMedGoogle Scholar
• Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105:1715–1720.
   PubMed Web of Science ®Google Scholar
• Doan S, Gabison E, Gatinel D, et al. Topical cyclosporine A in severe steroid-dependent childhood plyctenular keratoconjunctivitis. Am J Ophthalmol. 2006; 141(1):62–66.
   PubMedGoogle Scholar
• Reinhard T, Sundmacher R. Topical cyclosporin A in Thygeson’s superficial punctuate keratitis. Graefes Arch Clin Exp Ophthalmol. 1999;237(2):109–112.
   PubMedGoogle Scholar
• Gundüz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome. Acta Ophthalmol. 1994;72(4):438–442.
   Google Scholar
• Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporine A. Ocul Immunol Inflamm. 2010;18(5):352–361.
   PubMedGoogle Scholar
• Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporine A in the treatment of anterior segment inflammatory disease. Cornea. 1993;12(5):413–419.
   PubMedGoogle Scholar
• Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical use. Surv Ophthalmol. 2009;54(3):321–338.
   PubMedGoogle Scholar